IMGN Stock Cash Flow Statements

ImmunoGen Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

ImmunoGen Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-03-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2014-09-30	2013-12-31	2013-09-30	2013-03-31	2012-12-31	2012-09-30	2011-09-30	2010-12-31	2010-09-30	2010-03-31	2009-12-31	2009-09-30	2008-09-30	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-03-31	2003-12-31	2003-09-30	2003-03-31	2002-12-31	2002-09-30	2002-03-31	2001-12-31	2001-09-30


cash flows from operating activities:
net income	30,748,000	-4,248,000	-41,014,000	-59,008,000	-77,755,000	-62,021,000	-24,145,000	-37,172,000	-37,339,000	-30,741,000	-34,051,000	31,388,000	-22,374,000	-24,298,000	-29,088,000	4,814,000	-21,750,000	-43,446,000	-43,751,000		-46,807,000	-41,624,000	-38,613,000	-17,345,000	-44,731,000	-45,922,000	-31,928,000	-33,227,000	-33,740,000	-22,282,000	3,812,000	-11,226,000	-1,351,000	-24,393,000	-25,192,000	-19,483,000	-14,233,000	-12,888,000	-12,124,000	-13,008,000	-12,375,000	-9,397,000	-6,212,000	-1,032,000		-5,160,000	-3,045,000	-6,253,000		-2,981,000	-3,502,000	-4,706,000	8,219,909	-3,550,976	-2,209,378	-2,470,506	-759,921	-1,332,609	-4,126,414	-4,616,581	-5,285,198	-3,221,537	-6,872,868	-1,732,252	-1,592,523
adjustments to reconcile net income to net cash from operating activities:
non-cash royalty revenue related to sale of future royalties																			-8,488,000		-8,441,000	-7,242,000	-7,190,000	-7,613,000	-6,184,000
non-cash interest expense on liability related to sale of future royalties																									5,018,000		4,972,000	5,059,000	5,143,000
non-cash interest expense on amortization of debt discount and issuance costs
depreciation and amortization	423,000	427,000	448,000	428,000	424,000	458,000	473,000	462,000	462,000	542,000	551,000	532,000	524,000	516,000	529,000	751,000	839,000	1,238,000	1,200,000		1,136,000	2,529,000	2,527,000	1,506,000	1,528,000	1,505,000	1,435,000	1,260,000	1,127,000	1,389,000	1,145,000	1,162,000	1,173,000	1,162,000	1,174,000	1,163,000	1,198,000	1,178,000	1,188,000	1,214,000	1,258,000	1,233,000	1,062,000	1,049,000	-2,120,847	722,000	711,000	691,000	664,000	692,000	682,000	650,000	-1,622,634	605,650	578,485	440,721	358,808	322,250	229,287	321,537	302,361	285,072	247,708	246,551	228,225
stock and deferred share unit compensation	7,874,000	7,433,000	7,067,000	10,753,000	5,482,000	4,973,000	4,407,000	6,433,000	3,477,000	3,742,000	3,823,000	3,867,000	3,878,000	3,454,000	3,122,000	3,228,000	3,626,000	2,206,000	5,107,000		4,410,000	4,025,000	3,847,000	2,665,000	4,497,000	4,580,000	7,283,000	4,602,000	5,783,000	5,410,000	3,753,000	4,795,000	2,991,000	2,928,000	3,920,000	2,568,000	1,582,000	1,478,000	1,096,000	1,241,000	1,104,000	1,355,000							585,000
change in operating assets and liabilities:
accounts receivable	-55,334,000	-48,018,000	-14,746,000	-12,554,000	867,000	281,000	3,277,000	-4,246,000	-214,000	86,000	-58,000	5,015,000	-4,737,000	-259,000	7,446,000	-7,406,000	-94,000	233,000	1,468,000	1,167,000	-2,096,000	15,000	2,615,000	-1,867,000	567,000	-779,000	699,000			58,000						4,667,000												-697,000	-70,000	415,000	-199,000	-297,000	-1,492,688	-2,284,459	1,528,651	2,251,942				157,494
unbilled receivable	-1,309,000	-468,000	282,000	-835,000	1,178,000	1,769,000	-1,298,000	2,361,000	-479,000	1,178,000	-5,394,000
inventory	-12,554,000	-4,309,000	-709,000																		-48,000	-1,522,000	670,000	-1,033,000	-1,120,000	1,000	629,000	-291,000	1,689,000	835,000			338,000	-280,000	1,118,000				9,000	138,000	464,000	297,000	1,065,000	179,000				-686,000	198,000	-14,000	-748,000	696,000	-4,809,406	2,141,457	1,301,378	1,371,689			28,657
contract asset																			500,000	1,000,000
prepaid and other current assets	-4,623,000	-3,134,000	50,000	5,709,000	-2,615,000	-5,292,000	-1,485,000	7,008,000	174,000	917,000	-7,520,000	-26,000	-1,449,000	1,227,000	-2,228,000	-464,000	1,688,000	61,000	-2,248,000	7,815,000	3,573,000	-4,213,000	-2,713,000	-1,008,000	-2,600,000				95,000	525,000			297,000			1,374,000	-255,000	513,000		-189,000	256,000	1,024,000					30,000	184,000	170,000	-514,000	48,000	396,000		105,015	-35,675	189,701	-386,987	57,666	395,012	217,176			-210,767	276,178	83,310
operating lease right-of-use assets																			348,000
other assets	141,000	196,000	-485,000	-911,000	-424,000	-4,004,000	39,000	-176,000	351,000	-1,561,000	3,661,000	-2,416,000	-979,000	-760,000	-3,047,000	-371,000	-1,563,000	1,815,000	44,000	3,853,000	496,000	244,000	-884,000	-173,000	292,000				62,000	105,000		14,000				17,000	-27,000	34,000				6,000	0	63,000	-46,953			48,000	0	0	0	48,000	-18,536	0	0	18,555
accounts payable	6,504,000	-13,924,000	-12,975,000	25,046,000	2,938,000	1,059,000	-2,308,000	7,794,000	-1,128,000	-1,320,000	3,802,000	209,000	-3,189,000	2,810,000	-649,000	2,706,000	-552,000	-501,000	-2,698,000	9,945,000	-2,451,000	4,628,000	-757,000	-2,543,000	-2,120,000	1,853,000	-2,378,000	1,623,000	1,551,000	138,000									-701,000			309,000			-855,120			522,000	-131,000	537,000	-412,000	-747,000					1,242,654	-51,061	1,133,510	1,874,235	277,535	178,423			17,363
accrued compensation	4,421,000	-1,047,000	670,000	2,490,000	3,661,000	1,552,000	-2,061,000	751,000	991,000	678,000	-1,571,000	551,000	-460,000	-924,000	-3,267,000	-4,525,000	-6,902,000	16,611,000	-7,373,000	12,953,000	1,792,000	2,853,000	-5,802,000	-2,019,000	-3,978,000																	317,000	998,000	144,000	-1,844,712	449,000	1,175,000	221,000	-1,021,000	-73,000	992,000	299,000	-2,012,082	885,589	390,559	736,090	787,679	231,007	532,745				470,205	135,882	377,212
other accrued liabilities	9,963,000	5,422,000	-7,913,000	-8,307,000	10,414,000	7,620,000	5,023,000	-12,414,000	5,299,000	-3,633,000	3,487,000	7,905,000	5,997,000	-2,421,000	5,253,000	-88,000	-712,000	-6,277,000	931,000	12,567,000	6,002,000	-3,551,000	5,447,000	775,000	38,000					29,000		438,000			2,896,000				-244,000	439,000	810,000				-1,128,653	281,000	568,000	281,000
deferred revenue	19,298,000	-2,893,000	-2,712,000	-3,600,000	-5,436,000	-10,864,000	-21,957,000	-13,937,000	-3,267,000	-765,000	-72,000	-20,417,000	3,911,000	-895,000	78,000	-18,420,000	-79,000	-79,000	65,208,000		534,000	3,679,000	-11,875,000						464,000							813,000				58,000	751,000	2,650,000		781,000				149,000	-2,002,000	-1,035,000	179,000	75,000					-187,878	-651,558	10,818,141				569,672
operating lease liability																			-556,000
net cash from operating activities	2,770,000	-66,741,000	-73,719,000	-60,199,000	-64,210,000	-63,991,000	-41,402,000	-45,874,000	-35,042,000	-43,879,000	-44,621,000	8,535,000	-30,647,000	-28,193,000	-28,315,000		-35,000,000					-35,326,000	-49,955,000	-32,959,000	-47,844,000																							-4,558,000	-7,207,000	-2,431,000	-1,180,000	-3,463,000				857,124	1,335,212	-5,845,971	6,485,326
cash flows from investing activities:
purchases of property and equipment								-369,000	-125,000	-47,000	-893,000	-102,000	-771,000	-23,000	-21,000	-83,000	-407,000	-228,000	-2,127,000		-2,093,000	-1,099,000	-1,028,000	-437,000	-1,182,000
net cash from investing activities	-1,354,000	-78,000	-209,000	-248,000	-602,000	-207,000	-307,000	-369,000	-125,000	-47,000	-893,000	-102,000	-771,000	-23,000	1,405,000	2,229,000	-407,000	-228,000	-2,127,000		-2,093,000	-1,099,000	-1,028,000	-437,000	-1,182,000												-486,000	949,000				2,118,000	-13,673,000	21,343,000	-12,373,577	4,351,000	2,047,000	5,995,000		-1,025,000	5,350,000	2,292,000		1,855,574						9,055,073	-312,566	7,366,010			610,764
cash flows from financing activities:
proceeds from issuance of common stock under stock plans	32,166,000	14,906,000	39,000	425,000	449,000	411,000	620,000	1,737,000	368,000	378,000	1,286,000	678,000	129,000	424,000	240,000	2,062,000	73,000	670,000	68,000
proceeds from term loan, net of 3,182 of issuance costs
proceeds from common stock issuance, net of 526 of transaction costs
net cash from financing activities	32,132,000	437,557,000	39,000	26,074,000	449,000	411,000	620,000	279,232,000	41,390,000	344,000	34,778,000	97,206,000	129,000	423,000	97,984,000	2,062,000	73,000	670,000	68,000			163,100,000	2,259,000			96,790,000	188,000	329,000	4,462,000	144,000	3,030,000	4,025,000	1,367,000	148,000	94,694,000	716,000	352,000	120,000	575,000	1,624,000	509,000	43,000	804,000	171,000	-1,634,850	1,380,000	231,000	26,000	66,000	818,000	25,000	241,000	-479,628	389,828	85,887	4,442	121,894	96,692	2,025				104,199	334,543	5,255,659
net change in cash and cash equivalents	33,548,000	370,738,000	-73,889,000	-34,373,000	-64,363,000	-63,787,000	-41,089,000	232,989,000	6,223,000	-43,582,000	-10,736,000	105,639,000	-31,289,000	-27,793,000	71,074,000	-28,266,000	-35,334,000	-30,571,000	8,144,000		-41,853,000	126,675,000	-48,724,000	-33,396,000	-49,026,000								-4,918,000	-22,593,000	72,676,000								-13,910,000	15,670,000	-2,509,208	2,146,000	-1,094,000	1,463,000	763,000	-2,638,000	4,195,000	-930,000		771,343	-16,209	173,917									1,876,964
cash and cash equivalents, beginning of period	0	0	275,138,000	0	0	0	478,750,000	0	0	0	293,856,000	0	0	0	176,225,000	0	0	0	262,252,000		0	0	267,107,000	159,964,000	245,026,000																		0	10,605,000
cash and cash equivalents, end of period	33,548,000	370,738,000	201,249,000	-34,373,000	-64,363,000	-63,787,000	437,661,000	232,989,000	6,223,000	-43,582,000	283,120,000	105,639,000	-31,289,000	-27,793,000	247,299,000	-28,266,000	-35,334,000	-30,571,000	270,396,000		-41,853,000	126,675,000	218,383,000	126,568,000	196,000,000
supplemental cash flow information:
cash paid during the year for interest	2,539,000
cash paid during the year for taxes	1,284,000
proceeds from common stock issuance, net of 493 of transaction costs
non-cash interest expense on liability related to sale of future royalties and convertible senior notes																			3,432,000		2,546,000	2,611,000	3,046,000	3,575,000
gain on sale/disposal of fixed assets and impairment charges																-855,000	140,000	1,960,000	444,000					180,000
proceeds from sale of equipment
payments upon settlement of convertible senior notes
proceeds from warrant issuance, net of 391 of transaction costs
proceeds from common stock issuance, net of 373 and 701 of transaction costs, respectively
proceeds from warrant issuance, net of 181 of transaction costs
proceeds from common stock issuance, net of 143 of transaction costs
proceeds from common stock issuance, net of 106 of transaction costs
proceeds from common stock issuance, net of 70 of transaction costs
(gain) loss on sale/disposal of fixed assets and impairment charges												0	0	18,000	-709,000						0	0	-30,000
operating lease right-of-use asset impairment																0	135,000
proceeds from common stock issuance, net of 143 and 230 of transaction costs, respectively
proceeds from common stock issuance, net of 106 and 230 of transaction costs, respectively
proceeds from common stock issuance, net of 70 and 229 of transaction costs, respectively
deferred rent																					-3,000	-74,000	15,000	25,000	63,000	64,000	41,000	27,000	29,000	92,000							14,000	8,000	8,000	19,000	14,000	692,000	924,000	5,000	-46,931	15,000	15,000	17,000	23,000	22,000	7,000	1,000	-3,602	1,203	1,202	1,202
proceeds from common stock issuance, net of 701 and 395 of transaction costs, respectively
unbilled revenue/reimbursement													0	1,748,000	-752,000	2,008,000	-535,000	1,508,000	-3,365,000
proceeds from common stock issuance, net of 230 of transaction costs
proceeds from common stock issuance, net of 229 of transaction costs
non-cash debt conversion expense
net cash (used) provided for operating activities
proceeds from common stock issuance, net of 395 and 222 of transaction costs, respectively
fees for debt conversion
proceeds from common stock issuance, net of 395 of transaction costs
proceeds from common stock issuance, net of 367 of transaction costs
net cash provided (used) for operating activities																			10,203,000
assets
cash and cash equivalents
unbilled revenue																				-1,442,000	1,000	2,316,000	-258,000	4,727,000	-51,000					545,000	75,000	142,000				390,000						121,000	130,000	1,611,000				317,000	10,000	-632,000	1,098,000	-860,000				983,441						117,497
non-cash royalty receivable
total current assets
property and equipment, net of accumulated depreciation
total assets
liabilities and shareholders’ equity
current portion of deferred lease incentive
current portion of liability related to the sale of future royalties, net of deferred financing costs of 753 and 772, respectively
current portion of deferred revenue
total current liabilities
deferred lease incentive, net of current portion
deferred revenue, net of current portion
convertible 4.5% senior notes, net of deferred financing costs of 36 and 50, respectively
liability related to the sale of future royalties, net of current portion and deferred financing costs of 1,536 and 2,373, respectively
other long-term liabilities
total liabilities
commitments and contingencies
shareholders’ deficit:
preferred stock, .01 par value; authorized 5,000 shares; no shares issued and outstanding
common stock, 0.01 par value; authorized 200,000 shares; issued and outstanding 149,400 and 132,526 shares as of december 31, 2018 and december 31, 2017, respectively
additional paid-in capital
accumulated deficit
total shareholders’ equity
total liabilities and shareholders’ equity
net cash (used) provided by operating activities
proceeds from stock options exercised																					124,000	560,000	2,259,000			182,000	188,000	329,000	4,462,000	144,000	3,030,000	4,025,000	1,367,000	163,000	688,000	716,000	352,000	120,000	575,000	1,624,000	509,000	43,000	804,000	171,000	-1,634,850	1,380,000	231,000	26,000	66,000	818,000	25,000	241,000	-479,628	389,828	85,887	4,442	121,894	96,692	2,025	0			66,793	277,242	222,267
net cash provided (used) for financing activities
deferred revenue, net of non-cash upfront license payment																								-12,811,000	-74,000
gain on sale/disposal of fixed assets																															0	20,000
impairment charge related to restructuring																									970,000
proceeds from landlord for tenant improvements																									41,000					393,000												750,000
(gain) loss on sale/disposal of fixed assets
gain on forward contracts																																				44,000						103,000
non-cash licensing fee
restricted cash																																				700,000	0	255,000	0	0	47,000	48,000
payments from settlement of forward contracts
proceeds from sale of future royalties, net of 5,865 of transaction costs
proceeds from issuance of convertible 4.5% notes, net of 3,392 of transaction costs
changes in operating assets and liabilities:
payments for transaction costs related to sale of future royalties
cash and cash equivalents, beginning balance																											0	0	278,109,000	142,261,000	0	194,960,000	0	0	160,938,000	191,206,000	0	109,156,000	0	0	69,639,000	31,619,000			-4,808,187	0	0	4,813,000	0	0	0	3,423,000	-6,761,287	0	0	6,768,055	0	0	10,132,389	0	0	16,233,408	0	0	14,822,519
cash and cash equivalents, ending balance																											-29,370,000	-35,560,000	247,843,000	121,798,000	3,250,000	174,838,000	-4,918,000	-22,593,000	233,614,000	179,765,000	33,544,000	94,942,000	-10,188,000	-7,421,000	58,641,000	31,209,000			-7,317,395	2,146,000	-1,094,000	6,276,000	763,000	-2,638,000	4,195,000	2,493,000	-7,693,683	771,343	-16,209	6,941,972	10,319,328	4,083,146	5,450,276	-1,554,050	-6,254,567	15,239,778	6,237,561	-2,854,608	16,699,483
proceeds from common stock issuance																																	0	-15,000	94,006,000
(gain) loss on forward contracts
amortization of deferred lease incentive obligation
proceeds (payments) from settlement of forward contracts																																									22,000
loss on forward contracts																																			2,000				65,000
amortization of deferred lease incentive
gain on sale of marketable securities																																																									525
proceeds from maturities or sales of marketable securities																																					0	1,201,000	116,000	119,000	509,000	2,830,000	4,562,000	21,744,000	-213,589,310	113,727,000	44,303,000	55,857,000	93,803,000	88,857,000	231,279,000	139,457,000	-782,333,777	315,040,695	253,214,204	215,146,639	70,017,855	72,018,496	91,428,415
(payments) proceeds from settlement of forward contracts
loss on sale/disposal of fixed assets																																					0	2,000	35,000
proceeds from settlement of forward contracts																																						96,000					211,000	69,000	-6,968
loss on sale of marketable securities																																										33,000						1,000	-5,000	7,000	22,000	4,000		55,074	1,005	3,106
other-than-temporary impairment of marketable securities
gain on sale of fixed assets																																																		0
other-than-temporary impairment of investments
impairment of investments																																										136,000
amortization of lease incentive obligation
gain on disposal of fixed assets
stock–based compensation
reclassification of cash equivalent balance to marketable securities
purchases of marketable securities																																																-49,369,000	-85,417,000	-89,425,000	-225,241,000	-136,669,000
proceeds from sale of fixed assets																																																	0	0	1,000	2,000
cash and cash equivalents, ending of period																																											-13,910,000	26,275,000
supplemental disclosure:
cash paid for income taxes																																											4,000	18,000	-31,966	12,000	5,000	15,000	0	7,000	0	10,000	-15,524	-13,691	11,250	18,000				0
loss on disposal of fixed assets																																												11,000
stock—based compensation																																												531,000
(gain) loss on disposal of fixed assets
stock-based compensation																																														611,000	614,000	647,000
capital expenditures																																																-493,000	-482,000	-457,000	-689,000	-498,000
free cash flows																																																-5,051,000	-7,689,000	-2,888,000	-1,869,000	-3,961,000
gain on derivative contracts
inventory write-down
other current accrued liabilities																																																	635,000	564,000	329,000	274,000				250,061					847,754	1,552,066
net cash from investing activity
inventory reserve																																																		-11,000
stock compensation																																																			540,000	706,000
repurchases of common stock
compensation for stock options, stock and stock units																																																						-49,388	176,721	2,925	135,193	21,248	21,463
deposit on construction in progress
non cash activities:
repurchases of common stock included in other accrued liabilities																																																													-219,216	576,602
capital expenditures included in accounts payable																																																															-376,739
(gain) loss on sale of marketable securities																																																											21,873
realized gains on sale of marketable securities
gain on sale of property and equipment
proceeds from sales and maturities of marketable securities																																																												94,638,529	71,096,017	92,059,231
proceeds from sale of property and equipment																																																															0
proceeds from warrants exercised																																																															40,226	60,011	5,035,999
principal payments on capital lease obligations
supplemental disclosures:
non-cash activities:
repurchases of common stock included in other current accrued liabilities
compensation for stock and stock units																																																													11,995	11,994	11,968
accrued financing fees
payment of deposit on construction in progress
cash paid for taxes																																																														29,000	317	0	66,912
cumulative effect of change in accounting principle
realized gain on sale of marketable securities
(gain)/loss on sale of property and equipment
due from related parties
sales and maturities (purchases) of marketable securities
earned and unbilled revenue
loss on sale of property and equipment
due from collaborative partners
sales or maturities (purchases) of marketable securities																																																																	1,162,816

We provide you with 20 years of cash flow statements for ImmunoGen stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ImmunoGen stock. Explore the full financial landscape of ImmunoGen stock with our expertly curated income statements.

The information provided in this report about ImmunoGen stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.